SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally has drawn attention to Starknets privacy and Bitcoin DeFi push, particularly shielded strkBTC and STRK20, alongside its post-quantum security positioning. Bulls see these developments and ongoing network building as drivers, while skeptics highlight token-unlock dilution and the tokens weak longer-term performance.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows selloff is drawing attention after Q2 results and a lower outlook: traders cite weaker expected residential revenue amid a sluggish housing market, despite revenue growth and strength in mortgages and rentals. Bulls call the decline an overreaction and point to growth and valuation, while bears focus on high mortgage rates, weak housing activity, and the guidance cut.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Attention centers on Compounds institutional-market push, including a reported launch, new leadership and investment plans, alongside anticipation for V4. Many traders are bullish on COMPs limited supply and potential breakout, while skeptics point to weak relative price action and concerns about protocol liquidity.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

TAO is drawing attention amid a recent price rebound, with traders debating whether the move can continue or give way to another pullback. Bulls point to Bittensors decentralized-AI ecosystem and subnet development, while cautious voices question adoption and near-term catalysts amid broader crypto and macro uncertainty.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Discussion centers on IntraBios reported acquisition, which traders are using as a valuation benchmark for Zevras Niemann-Pick franchise and as fuel for speculation that ZVRA could attract a buyer. Some see the recent strength as evidence the market is recognizing undervaluation, while others caution that the companies assets and prospects differ and that no buyout of Zevra is confirmed.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention for its rebound and ongoing consolidation, with traders sharing technical setups and watching whether momentum can extend. Bulls see room for further gains, while skeptics call the coin weak and expect a pullback.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being tied to the launch of confidential perpetual trading powered by Hyperliquid, with traders also highlighting the tokens AI-agent and cross-chain Intents narrative. The reaction is largely bullish, though some remain cautious about pullbacks and the earlier NEAR Intents exploit.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins rebound and consolidation are driving IBIT discussion, with many traders treating pullbacks as buying opportunities and anticipating further gains, while others warn that momentum could fade. The conversation is largely about Bitcoins direction rather than a confirmed IBIT-specific catalyst.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

XCN is drawing attention amid a modest rebound and ongoing consolidation, with traders focused on chart levels, returning volume and the prospect of a breakout. Some are buying dips and expecting momentum to build, while others warn that thin volume and repeated rallies that fade make the move look like a pump-and-dump; broader crypto-market weakness is also cited.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

Gold miners are drawing attention as traders assess whether GDXs correction is bottoming, with higher real yields and a stronger dollar cited as near-term pressure on gold and miners. Some see signs of a rebound and are buying dips, while others want confirmation and warn that the pullback may continue; longer-term bulls point to central-bank buying and concerns about debt and currency debasement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ 

Equity

Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.read more...

CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside  

Compass said on Tuesday that the FDA recommended a trial showing a survival benefit before the company files a biologics license application for tovecimig in previously treated advanced biliary tract cancer. 


Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug

Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig's FDA marketing application.read more...

 CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing

The FDA wants Compass to conduct a trial showing Tovecimig can improve overall survival in patients with previously treated, advanced biliary tract cancer.


A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Canaccord Genuity Group Lowers Compass Therapeutics (NASDAQ:CMPX) Price Target to $7.00

Canaccord Genuity Group dropped their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday...

Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX)

Citizens Jmp restated a "market outperform" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday...

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CMPX News